Economic burden of vulvar and vaginal intraepithelial neoplasia: Retrospective cost study at a German dysplasia centre

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Hampl, Monika ^a   Huppertz, Eduard ^b   Schulz Holstege, Olaf ^a   Kok, Patrick ^c   Schmitter, Sarah ^d  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Heinrich Heine Universtität ^*  (Germany)

^c Institut für Experimentelle Psychologie   (Germany)

^d Sanofi Pasteur MSD GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRODUCTIVITY; RETROSPECTIVE STUDY; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVECTOMY; COST; ECONOMICS; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CARCINOMA IN SITU; VAGINA TUMOR; VIROLOGY; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; COSTS AND COST ANALYSIS; FEMALE; GERMANY; HUMANS; INSURANCE, HEALTH; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 79953093601     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-73     Document Type: Article

References (26)

1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV Infection Among Females in the United States. JAMA 2007, 297:813-819. 10.1001/jama.297.8.813, 17327523.
2. Hu D, Goldie SJ. The Economic Burden of Noncervical Human Papillomavirus Disease in the United States. Am J Obstet Gynecol 2008, 198:500.e1-500.e7.
3. Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER. Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value Health 2008, 11:1022-1032. 10.1111/j.1524-4733.2008.00342.x, 18489503.
4. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006, 107:1018-1022. 10.1097/01.AOG.0000210268.57527.a1, 16648405.
5. Anders S, Riethdorf L, Loening TH. Neoplasien und Praeneoplasien des unteren Genitaltraktes. Gynäkologe 2001, 34:590-598.
6. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006, 108:1361-1368. 10.1097/01.AOG.0000245786.86267.80, 17138767.
7. Joura EA, Lösch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000, 45:613-615.
8. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005, 106:1319-1326. 10.1097/01.AOG.0000187301.76283.7f, 16319258.
9. Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006, 100:271-275. 10.1016/j.ygyno.2005.08.012, 16169064.
10. Hampl M, Wentzensen N, Vinokurova S, von Knebel-Doeberitz M, Poremba C, Bender HG, Kueppers V. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol 2007, 133:235-245. 10.1007/s00432-006-0162-0, 17294241.
11. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005, 97:645-651. 10.1016/j.ygyno.2005.02.012, 15863172.
12. Hording U, Junge J, Poulsen H, Lindvall F. Vulvar Intraepeitheal Neoplasia III: A Viral Disease of Undetermined Progressive Potentential. Gynecol Oncol 1995, 56:276-279. 10.1006/gyno.1995.1046, 7896198.
13. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C, . the Hanover Consensus Group German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. Value Health 2008, 11:539-544. 10.1111/j.1524-4733.2007.00301.x, 18194408, the Hanover Consensus Group.
14. GPS - Gute Praxis Sekundärdatenanalyse: Revision nach grundlegender Überarbeitung. , http://www.dgepi.de/pdf/infoboard/stellungnahme/gps-version2-final.pdf
15. Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008, 29:245-249.
16. Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study. BMC Infectious Diseases 2008, 8:76. 10.1186/1471-2334-8-76, 2438362, 18518976.
17. Rémy V, Mathevet P, Vainchtock A. Vulvar and vaginal cancers and dysplasia in France--An analysis of the hospital medical information system (PMSI) database. Eur J Obstet Gynecol 2009, 147:210-221.
18. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US--analytic framework and review of the literature. PharmacoEcon 2005, 23:1107-1122.
19. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang SH. The health and productivity cost burden of the top 10 physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med 2003, 45:5-14. 10.1097/00043764-200301000-00007, 12553174.
20. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36:1397-1403. 10.1086/375074, 12766834.
21. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004, 36:11-19. 10.1363/3601104, 14982672.
22. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001, 137:337-341.
23. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004, 191:114-120. 10.1016/j.ajog.2004.01.042, 15295351.
24. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189. 10.1016/0167-6296(94)00044-5, 10154656.
25. Johannesson M, Karlsson G. The friction cost method: A comment. J Health Econ 1997, 16:249-255. 10.1016/S0167-6296(97)00006-4, 10173080.
26. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. Reply to Johanneson's and Karlsson's comment. J Health Econ 1997, 16:257-259.